Trial · NCT06267664
Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)
NCT06267664, Unknown, Hospital Clínico Universitario de Valladolid
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP). Trials, record NCT06267664. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06267664
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP)
- NCT number
- NCT06267664
- Status
- Unknown
- Enrollment
- 1,500 participants, estimated
- Lead sponsor
- Hospital Clínico Universitario de Valladolid
- Conditions
- Migraine, Migraine Disorders, Migraine With Aura, Headache Disorders
- Interventions
- Patients with migraine treated with triptans, Lasmiditan or Gepants
- First posted
- 2024-02-20
- Last updated
- 2024-02-21
Source ClinicalTrials.gov
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain freedom at 2 hours | Two hours after treatment intake | The percentage of subjects who become pain free at two hours after treatment, before the use of any rescue medication |
| Primary | Absence of the most bothersome symptom | Two hours after treatment intake | Absence of the most bothersome migraine-asso- ciated symptom at 2 hours after treatment |
| Secondary | Pain freedom at 8 hours | Eight hours after treatment intake | The percentage of subjects who become pain free at eight hours after treatment, before the use of any rescue medication |
| Secondary | Pain freedom at 24 hours | 24 hours after treatment intake | The percentage of subjects who become pain free at 24 hours after treatment, before the use of any rescue medication |
| Secondary | Sustained pain freedom | Twenty-four hours after treatment intake | percentage of subjects who are pain free at 2 hours with no use of rescue medication or relapse within 24 hours of the initial treatment. |
| Secondary | Total freedom from migraine at 2 hours | Two hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at two hours |
| Secondary | Total freedom from migraine at 8 hours | Eight hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at eight hours |
| Secondary | Total freedom from migraine at 24 hours | Twenty-four hours after treatment intake | Percentage of subjects who report Freedom from headache and any migraine- associated symptoms at 24 hours |
| Secondary | Headache relief at 2 hours | Two hours after treatment intake | Percentage of subjects who report decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication |
| Secondary | Headache relief at 8 hours | Eight hours after treatment intake | Percentage of subjects who report decrease in headache pain from moderate or severe at baseline to mild or none at 2 hours after treatment and before taking any rescue medication |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers22
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06267664
GET https://conductscience.org/api/trials/v1/NCT06267664/registered?page=2